tbuckley/cabot-search huggingface dataset:
Abstract P406: Trend of Salt Consumption in Italy from 2009 to 2012
Authors: Chiara Donfrancesco, Pasquale Strazzullo, Daniela Galeone, Luigi Palmieri, Cinzia Lo Noce, Renato Ippolito, Ornella Russo, Diego Vanuzzo, Simona Giampaoli
Journal: Circulation (2014)

Background: Strategies aiming at reducing dietary sodium are being implemented in many countries based on evidence-based knowledge supporting their cost-effectiveness for reduction of cardiovascular and other chronic diseases. From 2009 to 2011 a Preventive Program of the Italian Ministry of Health has been implemented in Italy including the agreement with bread makers’ associations for the gradual reduction of the salt content in bread, public information campaigns, and the evaluation of population current dietary sodium intakes. This analyses aim to monitor dietary intake of sodium and potassium in representative samples of the Italian adult population before and after the Preventive Program. Methods: Data from random samples of persons aged 35-79 years and resident in Italian central regions were collected from October 2009 to September 2010 (299 men and 280 women) and from April to July 2012 (205 men and 210 women). Determinations of sodium and potassium were assessed in a centralized laboratory. Information on the consumption of high salt content food were collected through a questionnaire. Comparisons between mean levels and prevalences were performed using t-test and chi-squared test respectively. Results: In men, mean level of sodium chloride per day resulted 185 mmol (95% confidence interval: 177-193 mmol) in 2009-2010 samples and 161 mmol (152-169 mmol) in 2012 samples (p&lt;0.0001). In women, mean level of sodium chloride per day resulted 144 mmol (138-151 mmol) and 125 mmol (117-132 mmol) respectively (p=0.0001). Among men, sodium chloride excretion was higher than 85 mmol (the WHO recommended upper level for sodium intake) in 97% in 2009-2010 samples and 91% in 2012 samples (p=0.0026); among women in 86% and 73% respectively (p=0.0002). Among men, 23% have declared in 2009- 2010 to eat bread without salt often, while 40% in 2012 (p&lt;0.0001); in women 22% and 39% respectively (p=0.0001). No statistically significant differences were found between mean levels of potassium between samples collected in 2009- 2010 and samples of 2012. Conclusions: Presented data show that average daily sodium intake in central Italy is still largely higher than that recommended but a significant improvement of mean level of sodium intake and consumption of bread without salt resulted. This results fully justify and encourage the preventive initiatives for reduction of sodium intake and its monitoring in the general population.
Immunometabolism governs dendritic cell and macrophage function
Authors: Luke A.J. O’Neill, Edward J. Pearce
Journal: The Journal of Experimental Medicine (2015)

Recent studies on intracellular metabolism in dendritic cells (DCs) and macrophages provide new insights on the functioning of these critical controllers of innate and adaptive immunity. Both cell types undergo profound metabolic reprogramming in response to environmental cues, such as hypoxia or nutrient alterations, but importantly also in response to danger signals and cytokines. Metabolites such as succinate and citrate have a direct impact on the functioning of macrophages. Immunogenicity and tolerogenicity of DCs is also determined by anabolic and catabolic processes, respectively. These findings provide new prospects for therapeutic manipulation in inflammatory diseases and cancer.
Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.
Authors: E A Shafford, D W Rogers, J Pritchard
Journal: Journal of Clinical Oncology (1984)

Forty-two children, all over one year of age, were given vincristine, cyclophosphamide, and sequentially timed cisplatin and VM-26 (OPEC) or OPEC and doxorubicin (OPEC-D) as initial treatment for newly diagnosed stage III or IV neuroblastoma. Good partial response was achieved in 31 patients (74%) overall and in 28 (78%) of 36 patients whose treatment adhered to the chemotherapy protocol, compared with a 65% response rate achieved in a previous series of children treated with pulsed cyclophosphamide and vincristine with or without doxorubicin. Only six patients, including two of the six children whose treatment did not adhere to protocol, failed to respond, but there were five early deaths from treatment-related complications. Tumor response to OPEC, which was the less toxic of the two regimens, was at least as good as tumor response to OPEC-D. Cisplatin-induced morbidity was clinically significant in only one patient and was avoided in others by careful monitoring of glomerular filtration rate and hearing. Other centers should test the efficacy of OPEC or equivalent regimens in the treatment of advanced neuroblastoma.
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients
Authors: O. Glehen, D. Elias, F. N. Gilly, F. Boutitie, J. M. Bereder, F. Quenet, L. Sideris, B. Mansvelt, G. Lorimier
Journal: Journal of Clinical Oncology (2009)

4102 Background: Peritoneal carcinomatosis (PC) from non-gynecologic malignancies has long been regarded a terminal disease with a short median survival. Over the past decade, new locoregional therapeutic approaches combining cytoreductive surgery with perioperative intraperitoneal chemotherapy (PIC) have evolved and suggest improved survival. Methods: A retrospective multicentric study was performed in French speaking centers to evaluate the toxicity and the principal prognostic factors in order to identify the best indications. All patients had cytoreductive surgery and PIC (hyperthermic intraperitoneal chemotherapy (HIPEC) and or early postoperative intraperitoneal chemotherapy (EPIC)). Results: The study included 1290 patients from 25 institutions between February 1989 and December 2007. The principal etiologies of PC were colorectal adenocarcinoma (N=523), pseudomyxoma peritonei (N=301), gastric adenocarcinoma (N=159), peritoneal mesothelioma (N=88), and appendiceal adenocarcinoma (N=50). Mortality and morbidity rates were 4.1% and 33.8%, respectively. By multivariate analysis, age, extent of the PC, and the institution's experience had a significant influence on toxicity. The overall median survival was 34 months: 30 months for colorectal PC, not reached for pseudomyxoma peritonei, 9 months for gastric PC, 41 months for peritoneal mesothelioma, and 77 months for PC from appendiceal adenocarcinoma. Independent prognostic indicators by multivariate analysis were the institution's experience, etiology, completeness of cytoreductive surgery, extent of carcinomatosis, and lymph node involvement. Conclusions: The therapeutic approach combining cytoreductive surgery with PIC may achieve long-term survival in a selected group of patients with PC from non-gynecologic origin with acceptable mortality and morbidity. This treatment should be reserved to experienced institutions involved in the management of PC. No significant financial relationships to disclose.
Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
Authors: Maiko Matsushita, Koji Ozawa, Saori Kanchi, Akane Uchiumi, Takuma Suzuki, Daiju Ichikawa, Eri Matsuki, Masatoshi Sakurai, Daiki Karigane, Hidenori Kasahara, Hideaki Nakajima, Shinichiro Okamoto, Yutaka Hattori
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Tyrosine kinase inhibitors (TKIs) have improved overall survival of patients with chronic myeloid leukemia (CML). Moreover, it has been reported that some of the patients achieve treatment-free remission (TFR) after cessation of TKIs, even though leukemic stem cells (LSC) of CML
Analysis of Online Ratings of Dermatologists
Authors: Christie Riemer, Monica Doctor, Robert P. Dellavalle
Journal: JAMA Dermatology (2015)

drome had multiple retinal hamartomas, cortical dysplasia, a subependymal giant cell astrocytoma, and renal angiomyolipomas.He was found to have a TSC2 (OMIM 191092) mutation.On dermatological examination, he had angiofibromas, 2 ungual fibromas, 2 shagreen patches, multiple hypomelanic macules of the limbs and trunk, and dental enamel pits.Bier spots were noted on the upper limbs.Patient 4. A young patient having TSC with angiofibromas and epilepsy had cortical dysplasia and renal angiomyolipomas.On dermatological examination at age 18 years, he manifested angiofibromas, dental enamel pits, and hypomelanic macules, as well as pale macules of the limbs, especially on the forearms, which were noted to be Bier spots.Discussion | In this series, 4 of 29 patients with TSC (14%) had nevus anemicus or Bier spots.Nevus anemicus has been reported in patients with type 1 neurofibromatosis, 5 phakomatosis pigmentovascularis, 6 and port-wine stains. 7Bier spots are a common insignificant finding.These vascular manifestations could be minor cutaneous markers of TSC, occurring in a subgroup of patients with the disease.Compared with the aesthetically disfiguring facial angiofibromas, these minor skin signs may go unnoticed and are usually of no concern to the patient.Future research is needed to determine if these signs are significant within the context of TSC.
When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults
Authors: Kristen M. O’Dwyer, Anjali S. Advani
Journal: Journal of Clinical Oncology (2015)

A 23-year-old man was urgently referred for evaluation of rapidly enlarging cervical lymphadenopathy, progressive dyspnea, fatigue, night sweats, and an unintentional weight loss of 25 pounds. A computed tomography scan of the neck performed 30 days before referral revealed bilateral cervical and supraclavicular lymphadenopathy (6 × 5 cm). A fine-needle aspirate of nasopharyngeal tissue demonstrated fibroadipose tissue. Tissue collected by core needle biopsy of a left internal jugular lymph node demonstrated a reactive lymph node but no malignancy. The patient was admitted to an academic medical center hospital. His physical examination was remarkable for bulky cervical and supraclavicular lymphadenopathy. A testicular examination was normal. The patient's lactate dehydrogenase concentration was 327 U/L (normal range, 118-225 U/L). A positron emission tomography scan revealed bilateral cervical and supraclavicular lymphadenopathy (6 × 5 cm with a standardized uptake value [SUV] of 14), a 1.3-cm subcutaneous nodule in the left thigh (SUV 16), and two 2.7-cm liver lesions (SUV 14). He underwent an excisional lymph node biopsy. The lymph node revealed effacement of the architecture by an interfollicular infiltrate of lymphoid cells (Fig 1). Mitotic figures were abundant (Ki-67 stain 80% to 90% positive) and there were multiple foci of tissue necrosis. The lymphoblasts were examined by flow cytometry and immunohistochemistry and expressed the T-cell markers CD2, CD3, CD4, and terminal deoxynucleotidyl transferase. A subpopulation of T cells was positive for both CD4 and CD8. Polymerase chain reaction studies revealed a clonal rearrangement of the T-cell receptor γ gene. A marrow aspirate and biopsy revealed normal trilineage hematopoiesis with no evidence of lymphoma and a normal male karyotype (46, XY). A lumbar puncture sample did not contain lymphoma cells. The patient's diagnosis was T-lymphoblastic lymphoma.
Charachterization and functional analysis of scFv-based CARs to redirect T cells to IL13Rα2-positive glioma
Authors: Giedre Krenciute, Simone Krebs, David Torres, Gianpietro Dotti, Maciej S Lesniak, Irina V Balyasnikova, Stephen Gottschalk
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts The goal of this project is to develop T cells that express chimeric antigen receptors (CARs) as an effective immunotherapy for glioblastoma (GBM), the most aggressive, primary brain tumor in humans, which outcome remains poor. IL13Rα2 is aberrantly expressed in GBM and therefore
Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013
Authors: E. Sbidian, C. Hotz, J. Seneschal, A. Maruani, F. Amelot, F. Aubin, C. Paul, M. Beylot Barry, P. Humbert, A. Dupuy, F. Caux, N. Dupin, P. Modiano, P. Lepesant, S. Ingen-Housz-Oro, E. Mahé, H. Bachelez, O. Chosidow, P. Wolkenstein
Journal: British Journal of Dermatology (2015)

Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin disease typically characterized by recurrent painful, deep inflammatory nodules of the axillary, breast, groin and gluteal areas. European recommendations are mainly based on expert opinion. Drug treatments are heterogenous (e.g., antibiotics, corticosteroids, retinoids) and lack consensus among expert centres. The most severe disease forms or those failing to respond to conventional drugs may be associated with worsened functional prognosis. Anti-tumor necrosis factor α (anti-TNFα) drugs have been prescribed in these cases. The results of randomized controlled trials (RCTs) are discordant. Three RCTs concluded to the efficacy of adalimumab (ADA), and two others did not detect any difference between infliximab (IFX) or etanercept (ETA) and placebo. Finally, data from the literature and reported experiences do not conclude on the efficacy of anti-TNFα drugs for HS. This article is protected by copyright. All rights reserved
Idiopathic Pulmonary Hemosiderosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetics affect lung disease and smoking behaviour, study finds
Authors: Zosia Kmietowicz
Journal: BMJ (2015)

Researchers from the United Kingdom have identified genetic differences that affect the likelihood of whether a person will smoke and the predisposition of heavy smokers and non-smokers to poor lung health.

A study by the UK Biobank Lung Exome Variant Evaluation (UK BiLEVE) team analysed genetic data from UK Biobank (ukbiobank.ac.uk), which recruited 500 000 volunteers aged 40-69 from 2006 to 2010 across the UK for long term follow-up of their health, including collection of blood samples for genetic …
Biphosphonates and the Flare Phenomenon
Authors: Ibrahim Barista
Journal: Journal of Clinical Oncology (1999)

Article Tools Correspondence Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1999.17.4.1326b Journal of Clinical Oncology - published online before print September 21, 2016 Biphosphonates and the Flare Phenomenon Ibrahim BaristaxIbrahim BaristaSearch for articles by this author Show More Institute of Oncology, Hacettepe University, Ankara, Turkey https://doi.org/10.1200/JCO.1999.17.4.1326b First Page Full Text PDF Figures and Tables © 1999 by American Society of Clinical Oncology
Role of academia, government and pharmaceutical industry in early-phase clinical trials of novel cancer immunotherapies
Authors: L. S. Pan, D. Harris, E. A. McDermott, J. C. Skipper, E. W. Hoffman, L. J. Old, S. L. White
Journal: Journal of Clinical Oncology (2005)

6061 Background: This study was initiated to assess the levels of involvement of Academia, Government and Industry in Phase I and II clinical trials of novel cancer immunotherapies. Methods: Two databases, ClinicalTrials.gov, maintained by National Institutes of Health (NIH), and Cancer.gov, maintained by the National Cancer Institute (NCI), were selected for review on the basis of the number of trials of novel immunotherapies, and the level of information provided. Over the month of July 2003, each database was extensively mined for all Pilot, Phase I, I/II and II trials listed as active, completed or suspended. There were 482 trial records gathered from Cancer.gov, and 600 trial records gathered from ClinicalTrials.gov. The datasets were combined, and duplicate studies were eliminated to yield a final, non-redundant dataset of 758 trials. Results: ClinicalTrials.gov identified Academia/Government collaborations as sponsor of 45% of trials, Government and Industry as sole sponsor in 36% and 10% of trials respectively. Cancer.gov showed a large difference in the roles of Academia and Government with Government sponsoring 75% of trials and Academia sponsoring 8% of trials. In contrast, Industry was the sole reagent provider in 82% of trials, and a co-provider in an additional 8% of trials. We were unable to fully ascertain the roles of Industry, Government and Academia, as the databases did not use standardized terms and definitions, nor did they provide complete data. Moreover, both registries - one of which is proposed to be the mandated repository for clinical trials information - contained data that were inaccurate and erroneous. Conclusions: Collaboration between Industry, Academia and Government is the most frequent mechanism of conducting early phase clinical trials. Although not always the sponsor, Industry plays a dominant role in early phase cancer immunotherapy studies by providing up to 90% of study reagents used. Significant improvements to the current clinical trial registries are required to ensure complete and accurate recording of clinical trial information. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration LICR
Cancer immunenet biomarker profiling panel
Authors: Alex Chenchik, Mikhail Makhanov, Leonid Iakoubov, Costa Frangou
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Several recent studies have now firmly established a link between the immune infiltrate in several human carcinoma types and prognosis and/or response to therapy. Correspondingly, increasing evidence suggests that the number, type, and location of tumor-infiltrating lymphocytes in
Diabetic nephropathy
Authors: J N Harvey
Journal: BMJ (2002)

Nephropathy and renal failure remain a major complication of diabetes. New drugs have been developed, and clinical trials have established improved methods of preventing progression of nephropathy to end stage renal failure, yet the proportion of patients with diabetic nephropathy on chronic dialysis programmes is rising. In the United States diabetes has become the most common cause of end stage renal failure in patients starting dialysis.1 In the United Kingdom the figures are progressively increasing. How has this come about?

There are important differences between type 1 and type 2 diabetes. Among white patients in the United Kingdom with type 1 diabetes of 15-30 years' duration, fewer than 20% will have established nephropathy.2 This is broadly comparable to other European centres, although surveys in the United States show higher numbers and data from Sweden show lower numbers.2 The prevalence of nephropathy is higher among patients of Asian or African-Caribbean origin. Although the proportion of patients with type 1 diabetes and nephropathy has reduced over the past 20 years, the increasing incidence of type 1 diabetes over this period will increase the absolute numbers of patients reaching end stage renal failure. In addition, patients with type …
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Authors: Tetyana Pertseva, Kateryna Gashynova, Olena Bratus, Natalya Petrik
Journal: European Respiratory Journal (2013)

Aim: To evaluate plasma SP-D in pts with S COPD and during AE COPD in comparison with healthy control.

Study population: 44 pts with S COPD, 12 pts with AE COPD and 26 healthy persons made the study sample.

Methods: Medical history, SP-D in plasma by ELISA (Hycult Biotech, Netherlands), Spirometry by Masterscope (Viasis, Germany) were performed in all study population. Results: SP-D levels in groups are shown in the table 1.

View this table:



Conclusions: 

1. Both S and AE COPD pts have significantly higher plasma SP-D level, than healthy control.

2. Tendency to increasing of plasma SP-D was found in pts with AE COPD in comparison with S COPD. However this difference was not statistically significant.

3. Probably, plasma SP-D more likely reflects chronic lung inflammation, than acute injury in pts with COPD.
Pioglitazone Use and Risk of Bladder Cancer
Authors: Benjamin J. Davies
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mycosis Fungoides, Sezary Syndrome or T-Cell Prolymphocytic Leukemia?.
Authors: Pulini Stefano, Rupoli Serena, Scortechini Anna Rita, Tassetti Angela, Goteri Gaia, Bartocci Chiara, Discepoli Giancarlo, Mulattieri Simonetta, Brunori Marino, Leoni Pietro
Journal: Blood (2005)
Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction
Authors: Hendrik B. Sager, Timo Heidt, Maarten Hulsmans, Partha Dutta, Gabriel Courties, Matthew Sebas, Gregory R. Wojtkiewicz, Benoit Tricot, Yoshiko Iwamoto, Yuan Sun, Ralph Weissleder, Peter Libby, Filip K. Swirski, Matthias Nahrendorf
Journal: Circulation (2015)

Myocardial infarction (MI) is an ischemic wound that recruits millions of leukocytes. MI-associated blood leukocytosis correlates inversely with patient survival, yet the signals driving heightened leukocyte production after MI remain incompletely understood.